WilmerHale Advises Patient Square Capital's Platform Enavate Sciences on $125 Million Series A Financing for Ambros Therapeutics

WilmerHale Advises Patient Square Capital's Platform Enavate Sciences on $125 Million Series A Financing for Ambros Therapeutics

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Patient Square Capital's platform Enavate Sciences in its co-led, oversubscribed $125 million Series A financing to launch Ambros Therapeutics (Ambros). Ambros is a clinical-stage biotechnology company advancing late-stage therapies for severe, underserved diseases, beginning with neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1). The financing is expected to support the neridronate pivotal Phase 3 clinical trial in CRPS-1 (CRPS-RISE), as well as related regulatory preparations and pre-commercial activities.

The WilmerHale team was led by Palo Alto Partners Daniel Zimmermann and Jekkie Kim and included Associate Ben Goldfein.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel